[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Short Bowel Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

May 2024 | 128 pages | ID: S360C8FA0954EN
IMARC Group

US$ 6,499.00

E-mail Delivery (PDF), Hard Copy Mail Delivery, CD-ROM Mail Delivery

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
The 7 major short bowel syndrome markets are expected to exhibit a CAGR of 20.52% during 2024-2034.

The short bowel syndrome market has been comprehensively analyzed in IMARC's new report titled "Short Bowel Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Short bowel syndrome is a complex gastrointestinal disorder characterized by the inadequate functional length of the small intestine, often resulting from surgical resection or congenital conditions. It significantly impairs the body's ability to absorb nutrients and fluids, leading to a range of symptoms and nutritional deficiencies. Some of the common indications of this syndrome include severe diarrhea, malnutrition, dehydration, electrolyte imbalances, weight loss, and fatigue. Individuals suffering from the illness may also experience abdominal cramps, bloating, and an increased risk of developing complications like infections and kidney stones due to the malabsorption of key nutrients. The diagnosis of short bowel syndrome involves a combination of clinical evaluation, medical history review, physical exam, and various laboratory tests. Imaging techniques like X-rays, CT scans, and endoscopy can help to assess the length and function of the remaining intestine. The healthcare providers will further conduct blood workups to reveal nutritional deficiencies and electrolyte imbalances in patients.

The increasing cases of malabsorptive disorder resulting from the surgical removal of a significant segment of the small intestine, leading to an inadequate surface area for nutrient absorption, are primarily driving the short bowel syndrome market. In addition to this, the inflating utilization of essential medications, such as growth hormones, glutamine, anti-diarrheal agents, etc., to enhance intestinal absorption and manage associated symptoms is also creating a positive outlook for the market. Moreover, the widespread adoption of microbiome modulation techniques, since they involve manipulating the gut microbiota to improve nutrient uptake and intestinal health in individuals suffering from the disorder, is further bolstering the market growth. Apart from this, the rising demand for intestinal rehabilitation programs that focus on dietary adjustments, medication optimization, and parenteral nutrition tapering to boost the quality of life and enhance treatment outcomes is acting as another significant growth-inducing factor. Additionally, the emerging popularity of surgical interventions, such as intestinal transplantation, to treat patients who are non-responsive to other therapies is also augmenting the market growth. Furthermore, advances in regenerative medicine, which aims to regenerate or replace damaged intestinal tissue using stem cells and tissue engineering, are expected to drive the short bowel syndrome market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the short bowel syndrome market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for short bowel syndrome and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the short bowel syndrome market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the short bowel syndrome market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the short bowel syndrome market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current short bowel syndrome marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the short bowel syndrome market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the short bowel syndrome market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the short bowel syndrome market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of short bowel syndrome across the seven major markets?
What is the number of prevalent cases (2018-2034) of short bowel syndrome by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of short bowel syndrome by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with short bowel syndrome across the seven major markets?
What is the size of the short bowel syndrome patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of short bowel syndrome?
What will be the growth rate of patients across the seven major markets?

Short Bowel Syndrome: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for short bowel syndrome drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the short bowel syndrome market?
What are the key regulatory events related to the short bowel syndrome market?
What is the structure of clinical trial landscape by status related to the short bowel syndrome market?
What is the structure of clinical trial landscape by phase related to the short bowel syndrome market?
What is the structure of clinical trial landscape by route of administration related to the short bowel syndrome market?
1 PREFACE

2 SCOPE AND METHODOLOGY

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
  2.3.1 Primary Sources
  2.3.2 Secondary Sources
2.4 Market Estimation
  2.4.1 Bottom-Up Approach
  2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 SHORT BOWEL SYNDROME - INTRODUCTION

4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence

5 SHORT BOWEL SYNDROME - DISEASE OVERVIEW

5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 PATIENT JOURNEY

7 SHORT BOWEL SYNDROME - EPIDEMIOLOGY AND PATIENT POPULATION

7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
  7.2.1 Epidemiology Scenario (2018-2023)
  7.2.2 Epidemiology Forecast (2024-2034)
  7.2.3 Epidemiology by Age (2018-2034)
  7.2.4 Epidemiology by Gender (2018-2034)
  7.2.5 Diagnosed Cases (2018-2034)
  7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
  7.3.1 Epidemiology Scenario (2018-2023)
  7.3.2 Epidemiology Forecast (2024-2034)
  7.3.3 Epidemiology by Age (2018-2034)
  7.3.4 Epidemiology by Gender (2018-2034)
  7.3.5 Diagnosed Cases (2018-2034)
  7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
  7.4.1 Epidemiology Scenario (2018-2023)
  7.4.2 Epidemiology Forecast (2024-2034)
  7.4.3 Epidemiology by Age (2018-2034)
  7.4.4 Epidemiology by Gender (2018-2034)
  7.4.5 Diagnosed Cases (2018-2034)
  7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
  7.5.1 Epidemiology Scenario (2018-2023)
  7.5.2 Epidemiology Forecast (2024-2034)
  7.5.3 Epidemiology by Age (2018-2034)
  7.5.4 Epidemiology by Gender (2018-2034)
  7.5.5 Diagnosed Cases (2018-2034)
  7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
  7.6.1 Epidemiology Scenario (2018-2023)
  7.6.2 Epidemiology Forecast (2024-2034)
  7.6.3 Epidemiology by Age (2018-2034)
  7.6.4 Epidemiology by Gender (2018-2034)
  7.6.5 Diagnosed Cases (2018-2034)
  7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
  7.7.1 Epidemiology Scenario (2018-2023)
  7.7.2 Epidemiology Forecast (2024-2034)
  7.7.3 Epidemiology by Age (2018-2034)
  7.7.4 Epidemiology by Gender (2018-2034)
  7.7.5 Diagnosed Cases (2018-2034)
  7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
  7.8.1 Epidemiology Scenario (2018-2023)
  7.8.2 Epidemiology Forecast (2024-2034)
  7.8.3 Epidemiology by Age (2018-2034)
  7.8.4 Epidemiology by Gender (2018-2034)
  7.8.5 Diagnosed Cases (2018-2034)
  7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
  7.9.1 Epidemiology Scenario (2018-2023)
  7.9.2 Epidemiology Forecast (2024-2034)
  7.9.3 Epidemiology by Age (2018-2034)
  7.9.4 Epidemiology by Gender (2018-2034)
  7.9.5 Diagnosed Cases (2018-2034)
  7.9.6 Patient Pool/Treated Cases (2018-2034)

8 SHORT BOWEL SYNDROME - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm

9 SHORT BOWEL SYNDROME - UNMET NEEDS

10 SHORT BOWEL SYNDROME - KEY ENDPOINTS OF TREATMENT

11 SHORT BOWEL SYNDROME - MARKETED PRODUCTS

11.1 List of Short Bowel Syndrome Marketed Drugs Across the Top 7 Markets
  11.1.1 Gattex (Teduglutide) - Takeda
    11.1.1.1 Drug Overview
    11.1.1.2 Mechanism of Action
    11.1.1.3 Regulatory Status
    11.1.1.4 Clinical Trial Results
    11.1.1.5 Sales Across Major Markets
  11.1.2 NutreStore (Glutamine) - Emmaus Medical
    11.1.2.1 Drug Overview
    11.1.2.2 Mechanism of Action
    11.1.2.3 Regulatory Status
    11.1.2.4 Clinical Trial Results
    11.1.2.5 Sales Across Major Markets
  11.1.3 Zorbtive (Somatropin) - Merck Serono
    11.1.3.1 Drug Overview
    11.1.3.2 Mechanism of Action
    11.1.3.3 Regulatory Status
    11.1.3.4 Clinical Trial Results
    11.1.3.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 SHORT BOWEL SYNDROME - PIPELINE DRUGS

12.1 List of Short Bowel Syndrome Pipeline Drugs Across the Top 7 Markets
  12.1.1 Apraglutide - VectivBio
    12.1.1.1 Drug Overview
    12.1.1.2 Mechanism of Action
    12.1.1.3 Clinical Trial Results
    12.1.1.4 Safety and Efficacy
    12.1.1.5 Regulatory Status
  12.1.2 Glepaglutide - Zealand Pharma
    12.1.2.1 Drug Overview
    12.1.2.2 Mechanism of Action
    12.1.2.3 Clinical Trial Results
    12.1.2.4 Safety and Efficacy
    12.1.2.5 Regulatory Status
  12.1.3 HM15912- Hanmi Pharmaceutical
    12.1.3.1 Drug Overview
    12.1.3.2 Mechanism of Action
    12.1.3.3 Clinical Trial Results
    12.1.3.4 Safety and Efficacy
    12.1.3.5 Regulatory Status
  12.1.4 ALC 078 - Alcresta Therapeutics
    12.1.4.1 Drug Overview
    12.1.4.2 Mechanism of Action
    12.1.4.3 Clinical Trial Results
    12.1.4.4 Safety and Efficacy
    12.1.4.5 Regulatory Status
  12.1.5 NST 6179 - NorthSea Therapeutics
    12.1.5.1 Drug Overview
    12.1.5.2 Mechanism of Action
    12.1.5.3 Clinical Trial Results
    12.1.5.4 Safety and Efficacy
    12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. SHORT BOWEL SYNDROME - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. SHORT BOWEL SYNDROME – CLINICAL TRIAL LANDSCAPE

14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events

15 SHORT BOWEL SYNDROME - MARKET SCENARIO

15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
  15.2.1 Short Bowel Syndrome - Market Size
    15.2.1.1 Market Size (2018-2023)
    15.2.1.2 Market Forecast (2024-2034)
  15.2.2 Short Bowel Syndrome - Market Size by Therapies
    15.2.2.1 Market Size by Therapies (2018-2023)
    15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
  15.3.1 Short Bowel Syndrome - Market Size
    15.3.1.1 Market Size (2018-2023)
    15.3.1.2 Market Forecast (2024-2034)
  15.3.2 Short Bowel Syndrome - Market Size by Therapies
    15.3.2.1 Market Size by Therapies (2018-2023)
    15.3.2.2 Market Forecast by Therapies (2024-2034)
  15.3.3 Short Bowel Syndrome - Access and Reimbursement Overview
15.4 Market Scenario - Germany
  15.4.1 Short Bowel Syndrome - Market Size
    15.4.1.1 Market Size (2018-2023)
    15.4.1.2 Market Forecast (2024-2034)
  15.4.2 Short Bowel Syndrome - Market Size by Therapies
    15.4.2.1 Market Size by Therapies (2018-2023)
    15.4.2.2 Market Forecast by Therapies (2024-2034)
  15.4.3 Short Bowel Syndrome - Access and Reimbursement Overview
15.5 Market Scenario - France
  15.5.1 Short Bowel Syndrome - Market Size
    15.5.1.1 Market Size (2018-2023)
    15.5.1.2 Market Forecast (2024-2034)
  15.5.2 Short Bowel Syndrome - Market Size by Therapies
    15.5.2.1 Market Size by Therapies (2018-2023)
    15.5.2.2 Market Forecast by Therapies (2024-2034)
  15.5.3 Short Bowel Syndrome - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
  15.6.1 Short Bowel Syndrome - Market Size
    15.6.1.1 Market Size (2018-2023)
    15.6.1.2 Market Forecast (2024-2034)
  15.6.2 Short Bowel Syndrome - Market Size by Therapies
    15.6.2.1 Market Size by Therapies (2018-2023)
    15.6.2.2 Market Forecast by Therapies (2024-2034)
  15.6.3 Short Bowel Syndrome - Access and Reimbursement Overview
15.7 Market Scenario - Italy
  15.7.1 Short Bowel Syndrome - Market Size
    15.7.1.1 Market Size (2018-2023)
    15.7.1.2 Market Forecast (2024-2034)
  15.7.2 Short Bowel Syndrome - Market Size by Therapies
    15.7.2.1 Market Size by Therapies (2018-2023)
    15.7.2.2 Market Forecast by Therapies (2024-2034)
  15.7.3 Short Bowel Syndrome - Access and Reimbursement Overview
15.8 Market Scenario - Spain
  15.8.1 Short Bowel Syndrome - Market Size
    15.8.1.1 Market Size (2018-2023)
    15.8.1.2 Market Forecast (2024-2034)
  15.8.2 Short Bowel Syndrome - Market Size by Therapies
    15.8.2.1 Market Size by Therapies (2018-2023)
    15.8.2.2 Market Forecast by Therapies (2024-2034)
  15.8.3 Short Bowel Syndrome - Access and Reimbursement Overview
15.9 Market Scenario - Japan
  15.9.1 Short Bowel Syndrome - Market Size
    15.9.1.1 Market Size (2018-2023)
    15.9.1.2 Market Forecast (2024-2034)
  15.9.2 Short Bowel Syndrome - Market Size by Therapies
    15.9.2.1 Market Size by Therapies (2018-2023)
    15.9.2.2 Market Forecast by Therapies (2024-2034)
  15.9.3 Short Bowel Syndrome - Access and Reimbursement Overview

16 SHORT BOWEL SYNDROME - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 SHORT BOWEL SYNDROME MARKET - SWOT ANALYSIS

17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats

18 SHORT BOWEL SYNDROME MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX


More Publications